N Engl J Med 392(6):612615 Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
By enhancing the transport of acyl-CoA into mitochondria for oxidation, TC cells can utilize fatty acids as an alternative energy source more efficiently, highlighting the importance of lipid metabolism in supporting the growth and survival of TC cells
KhalifahR a ASuppreCHaidarARabasa-LhoretRLadouceurMLegaultL
Newbold RF, Overell RW
Consequently, this design aggravates the redox imbalance, causing a rapid increase in ROS in the short term in vitro, ultimately leading to the downstream signaling pathway activation and apoptosis of AML cells